Education
About Us
Working with TipRanks
Follow Us
Dogwood Therapeutics (DWTX)
NASDAQ:DWTX
DWTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.62 - $29.28
Previous CloseN/A
Volume14.38K
Average Volume (3M)2.06M
Market Cap
$9.40M
Enterprise Value$78.41M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)4.15M
Price to Earnings (P/E)―
Beta4.77
Next Earnings
May 08, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.16
Shares Outstanding1,911,128
10 Day Avg. Volume136,328
30 Day Avg. Volume2,059,259
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$30.00Price Target Upside640.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Business ExpansionThe business combination with Wex Pharmaceuticals expands the pipeline in the fatigue and pain space, enhancing Dogwood Therapeutics' position in the market.
Debt ManagementThe debt-to-equity conversion is seen as a derisking event for Dogwood as it removes all existing debt from the balance sheet.
Financial StrategyThe strategic financing agreement results in approximately $23 million of working capital to fund operations and advance the development of Halneuron.
Bears Say
Financial PerformanceDogwood Therapeutics reported a net loss of $2.3 million and ended the period with $2 million in cash on the balance sheet.
Shareholder ValueCurrent Virios shareholders are expected to account for approximately 6% of the new entity, suggesting a significant dilution of ownership.
---
Ownership Overview
63.00%
Insiders
0.79% Mutual Funds
<0.01% Other Institutional Investors
98.32% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
DWTX FAQ
What was Dogwood Therapeutics’s price range in the past 12 months?
Dogwood Therapeutics lowest stock price was $1.62 and its highest was $29.28 in the past 12 months.
What is Dogwood Therapeutics’s market cap?
Dogwood Therapeutics’s market cap is $9.40M.
When is Dogwood Therapeutics’s upcoming earnings report date?
Dogwood Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 34 days.
How were Dogwood Therapeutics’s earnings last quarter?
Dogwood Therapeutics released its earnings results on Mar 31, 2025. The company reported -$6.29 earnings per share for the quarter, missing the consensus estimate of -$3.7 by -$2.59.
Is Dogwood Therapeutics overvalued?
According to Wall Street analysts Dogwood Therapeutics’s price is currently Undervalued.
Does Dogwood Therapeutics pay dividends?
Dogwood Therapeutics does not currently pay dividends.
What is Dogwood Therapeutics’s EPS estimate?
Dogwood Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dogwood Therapeutics have?
Dogwood Therapeutics has 1,911,128 shares outstanding.
What happened to Dogwood Therapeutics’s price movement after its last earnings report?
Dogwood Therapeutics reported an EPS of -$6.29 in its last earnings report, missing expectations of -$3.7. Following the earnings report the stock price went down -11.17%.
Which hedge fund is a major shareholder of Dogwood Therapeutics?
Currently, no hedge funds are holding shares in DWTX
---
Company Description
Dogwood Therapeutics
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
---
DWTX Earnings Call
Q3 2024
0:00 / 0:00
---
DWTX Stock 12 Month Forecast
Average Price Target
$30.00
▲(640.74% Upside)
Technical Analysis
Best Analysts Covering DWTX
1 Year
1 Year Success Rate
0/6 ratings generated profit
1 Year Average Return
-25.98%
reiterated a buy rating 22 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -25.98% per trade.
---